scholarly journals 408 Long-term treatment with dupilumab minimizes use of systemic immunosuppressants as rescue medications in adults with moderate-to-severe atopic dermatitis

2020 ◽  
Vol 140 (7) ◽  
pp. S53
Author(s):  
L.A. Beck ◽  
A. Blauvelt ◽  
L. Sher ◽  
I. Hussain ◽  
A.B. Rossi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Term Treatment ◽  
Severe Atopic Dermatitis ◽  
Long Term Treatment

scholarly journals Long-term Treatment of Severe Recalcitrant Atopic Dermatitis with Omalizumab, an Anti-immuno-globulin E

2013 ◽  
Vol 93 (2) ◽  
pp. 206-208 ◽  
Author(s):  
S Quist ◽  
A Ambach ◽  
D Göppner ◽  
J Quist ◽  
I Franke ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Pediatric Atopic Dermatitis: Update on the Treatment Options

2020 ◽  
Vol 25 (4) ◽  
pp. 60-62
Author(s):  
Corina Adelina Zah ◽  
Andreea Emiliana Toporău ◽  
Paul Grama
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Treatment ◽  
Pediatric Patients ◽  
Treatment Options ◽  
Chronic Inflammatory Disease ◽  
Term Treatment ◽  
Phosphodiesterase 4 ◽  
Systemic Corticosteroids ◽  
Long Term Treatment

Abstract Atopic dermatitis (AD) is a chronic inflammatory disease characterized by skin dryness, pruritus and eczematous lesions with various periods of relapse. Symptomatology can appear in childhood and can persist in adulthood. Chronic treatment is required with corticosteroids being the standard options. The side effects of this type of long-term treatment represent a major concern for the pediatric patients. This review aims to give an update of the options used for treatment, apart from the systemic corticosteroids. Mild-to-moderate AD had a good response to creams containing fig and oatmeal extracts and inhibitors of phosphodiesterase-4 (crisaborole). In cases of severe AD, future treatment options could include monoclonal antibodies such as omalizumab and dupilumab

Sign in / Sign up

Export Citation Format

Share Document